Low-Carbohydrate Diet for the Treatment of Gestational Diabetes Mellitus

Moreno-Castilla, Cristina; Hernández, Marta; Bergua, M; Alvarez, Maria C.; Arce, Maria Angeles Castillo; Rodriguez, Karen; Martínez-Alonso, Montserrat; Iglesias, Montse; Mateu, M.; Santos, María Dolores; Pacheco, Linda Roxana; Blasco, Yolanda; Martin, E; Balsells, Nuria; Aranda, Núria; Mauricio, Daniel

doi:10.2337/dc12-2714

Cited by 74 publications

(66 citation statements)

References 17 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent RCTs in women with gestational diabetes suggest that a diet higher in complex carbohydrate and fiber, low in simple sugar (low glycemic index), and lower in saturated fat may be effective in blunting postprandial hyperglycemia, preventing worsened maternal insulin resistance and excess fetal growth 2021. In a recent crossover pilot study, 16 pregnant women with gestational diabetes were randomized to a higher complex carbohydrate (60%), lower fat (25%) diet or a conventional low carbohydrate (40% of calories), higher fat (45% of calories) diet at the time of diagnosis 22.…”

Section: Lifestyle Modificationsmentioning

confidence: 99%

Novel therapies for diabetes mellitus in pregnancy

Feghali

Scifres

2018

BMJ

View full text Add to dashboard Cite

Diabetes is a common complication of pregnancy, and the prevalence of all types of the disease is increasing worldwide. Diabetes in pregnancy is associated with short term and long term adverse effects for mother and child. The goal of treatment of diabetes in pregnancy is to minimize maternal and fetal adverse events related to hyperglycemia. Treatment options vary by type of diabetes, from a focus on lifestyle modifications in gestational diabetes to continuous glucose monitoring and insulin pumps in pregestational diabetes. Nevertheless, given the commonality of hyperglycemia, considerable overlap exists in the treatment of different types of diabetes in pregnancy. Also, despite ongoing research on treatment of diabetes in pregnancy for decades, changes in the characteristics of the patient population have highlighted the limited effectiveness of different therapies. Specifically, despite the co-occurrence of obesity and diabetes, treatment recommendations including glycemic targets are not altered in such cases and a single optimal treatment strategy for each type of diabetes in pregnancy does not seem to exist. Rather, the approach to treating pregnant women with diabetes likely needs to be individualized to maximize the short term and long term health of mother and child. This article will review recent clinical studies to summarize established treatment strategies and introduce novel therapies for diabetes in pregnancy.

show abstract

Section: Lifestyle Modificationsmentioning

confidence: 99%

Novel therapies for diabetes mellitus in pregnancy

Feghali

Scifres

2018

BMJ

View full text Add to dashboard Cite

show abstract

“…'Other' diet and exercise trials Nine trials 204,206,208,209,212,[215][216][217]219 were too methodologically diverse to allow pooling of data. Six trials 206,209,212,215,217,219 compared two different types of diets, one trial 204 compared exercise to insulin use, one trial compared diet and insulin to diet alone, and one compared exercise with diet 216 ( Table 28).…”

Section: Treatments For Gestational Diabetes: a Systematic Reviewmentioning

confidence: 99%

“…Asemi 215 Asemi 215 Asemi 215 Cao 217 Cao 217 Cypryk 209 Cypryk 209 Cypryk 209 Louie 219 Louie 219 Moreno-Castilla 206 Rae 212 Metformin, in addition to performing well, may also be preferred by women, as it is administered orally and can be stored at room temperature as opposed to insulin, which requires subcutaneous injection and refrigerated storage. Metformin is associated with gastrointestinal upset, however, which may affect compliance; unfortunately, few trials report side effects or participant satisfaction, quality of life or wellbeing, which should be examined by future trials.…”

Section: Pharmacological Treatmentsmentioning

confidence: 99%

See 1 more Smart Citation

The identification and treatment of women with hyperglycaemia in pregnancy: an analysis of individual participant data, systematic reviews, meta-analyses and an economic evaluation

Farrar

Simmonds

Griffin

et al. 2016

Health Technol Assess

View full text Add to dashboard Cite

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 11/99/02. The contractual start date was in June 2013. The draft report began editorial review in July 2015 and was accepted for publication in January 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. Published by the NIH...

show abstract

“…One RCT in 107 GDM patients showed that a low-GI diet (compared with the intake of all types of carbohydrates with varying GI) was not more efficient in the improvement of glycaemic control (14) . Inconsistent results were observed in other studies (15) , possibly due to insufficient appreciation of the total amount of carbohydrate in the foods, which is the major determinant for blood glucose response.…”

mentioning

confidence: 58%